Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients

Journal of the National Cancer Institute

Volumn 98, Issue 10, 2006, Pages 708-714

  Bohlius, Julia ^a   Wilson, Jayne ^b   Seidenfeld, Jerome ^c   Piper, Margaret ^c   Schwarzer, Guido ^d   Sandercock, Josie ^b   Trelle, Sven ^a   Weingart, Olaf ^a   Bayliss, Sue ^b   Djulbegovic, Benjamin ^e   Bennett, Charles L ^f   Langensiepen, Simon ^a   Hyde, Chris ^b   Engert, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Blue Cross and Blue Shield Association   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; DRUG RESPONSE; EMBASE; ERYTHROCYTE TRANSFUSION; HEAD AND NECK CANCER; HEART DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; MEDLINE; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; STATISTICAL SIGNIFICANCE; STROKE; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; INCIDENCE; IRON DEFICIENCY ANEMIA; METHODOLOGY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

ANEMIA, HYPOCHROMIC; ANTINEOPLASTIC AGENTS; EPOETIN ALFA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; INCIDENCE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK ASSESSMENT; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 33646905411     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj189     Document Type: Review

References (80)

1. Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage JO, Bennett CL, et al. Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14.
2. Clark O, Adams JR, Bennett CL, Djulbegovic B. Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer 2002;2:23.
3. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Erythropoietin for patients with malignant disease. Cochrane Libr 2005;4.
4. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, et al. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98.
5. Quirt I, Bramwell V, Charette M, Oliver T, and the Systemic Treatment Disease Site Group. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. Practice Guideline Report #12-1. Report #12-1; 2005.
6. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
7. Henke M, Laszig R, Ruebe C, Schaefer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
8. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-60.
9. Luksenburg H, Weir A, Wager R. FDA Briefing Document. Safety concerns associated with Aranesp (darbepoetin alfa) Amgen, Inc. and Procrit (epoetin alfa) Ortho Biotech, L.P., for the treatment of anemia associated with cancer chemotherapy: Hearings before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. May 4, 2004.
10. Food and Drug Administration. Oncologic Drugs Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/4037s2.htm. [Last accessed: March 15,H2006.] Available at: http://www.fda.gov/ohrms/ dockets/ac/04/briefing/4037b2.htm. [Last accessed: March 15, 2006.]
11. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival end-points. Stat Med 1998;17:2815-34.
12. Cascinu S, Fedeli A, Del Ferro E, Fedeli SL, Catalano G. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62.
13. Case DC Jr, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85: 801-6.
14. Henry DH, Brooks BJ Jr, Case DC Jr, Fishkin E, Jacobson R, Keller AM, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 1995;1:252-60.
15. Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer 1993;29a(Suppl 2): 2-8.
16. Hearings before the SubCommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. P-174. May 4, 2004.
17. Rose E, Rai K, Revicki D, Brown R, Reblando J. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994;84(10 Suppl 1):526a.
18. Ihaka R, Gentleman R. R: A language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.
19. Coiffier B, Boogaerts M, Kainz C. Impact of epoetin beta versus standard care on quality of life in patients with malignant disease. June 21, 2001. 6th Congress of the European Haematology Association, June 21-24, 2001, Frankfurt, Germany, Abstract #194.
20. Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113:172-9.
21. Italian Cooperative Study Group. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-4.
22. Kurz C, Marth C, Windbichler G, Lahousen M, Medl M, Vavra N, et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol Oncol 1997;65:461-6.
23. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study. Ann Oncol 1998;9:255-60.
24. Osterborg A, Boogaerts MA, Cimino R, Essers U, Holowiecki J, Juliusson G, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood 1996;87:2675-82.
25. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94.
26. Silvestris F, Romito A, Fanelli P, Vacca A, Dammacco F. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma. Ann Hematol 1995;70:313-8.
27. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 2000;95:1175-9.
28. Carabantes FJ, Benavides M, Trujillo R, Cobo M, Hebrero ML, Garcia S, et al. Epoetin alfa in the prevention of anemia in cancer patients undergoing platinum-based chemotherapy (CT). A prospective randomized study. Proceedings of ASCO. 1999. 35th Annual Meeting of the American Society of Clinical Oncology, May 15-18, 1999, Atlanta, GA. Abstract 18, 596a.
29. Henke M, Guttenberger R, Barke A, Pajonk F, Potter R, Frommhold H. Erythropoietin for patients undergoing radiotherapy: A pilot study. Radiother Oncol 1999;50:185-90.
30. Quirt I, Micucci S, Moran LA, Pater J, Browman G. The role of recombinant human erythropoietin (EPO) in reducing red blood cell transfusions and maintaining quality of life (QOL) in patients with lymphoma and solid tumors receiving cytotoxic chemotherapy. Results of a randomized, double-blind, placebo-controlled clinical trial. Blood 1996;88[10 (Suppl 1)]:347 (abstract 1378).
31. Ten Bokkel Huinink WW, De Swart CA, Van Toorn DW, Morack G, Breed WP, Hillen HF, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998;15:174-82.
32. Throuvalas NA, Antonadou D, Boufi M, Lavey R, et al. Erythropoietin decreases transfusion requirements during radiochemotherapy. Proceedings of ASCO. 2000. 36th Annual Meeting of the American Society of Clinical Oncology, May 20-24, 2000, New Orleans, LA. Abstract 1558.
33. Wurnig C, Windhager R, Schwameis E, Kotz R, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996;36:155-9.
34. Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, et al. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 1997;15:2715-21.
35. Dunphy FR, Harrison BR, Dunleavy TL, Rodriguez JJ, Hilton JG, Boyd JH. Erythropoietin reduces anemia and transfusions. Cancer 1999;86:1362-7.
36. Kunikane H, Watanabe K, Fukuoka M, Saijo N, Furuse K, Ikegami H, et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001;6:296-301.
37. Thatcher N, De Campos ES, Bell DR, Steward WP, Varghese G, Morant R, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 1999;80:396-402.
38. Welch RS, James RD, Wilkinson PM. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am 1995;1:261.
39. Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller Ziegler L, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response. Blood 1995;86:4446-53.
40. Aravantinos G, Linardou H, Makridaki D, Laiou E, Zafiropoulos A, Janninis J, et al. Recombinant human erythropoietin for platinum-based chemotherapy-induced anaemia: A single-centre randomised study. J Balkan Union Oncol 2003;8:127-32.
41. Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich D, Dewey C, et al. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86.
42. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
43. Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34.
44. Razzouk BI, Hockenberry M, Hinds PS, Rackoff W, Hord JD. A double-blind, placebo-controlled study of once-weekly epoetin alfa in children with cancer undergoing myelosuppressive chemotherapy. J Clin Oncol 22[14S]. June 5, 2004. 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. Abstract 8527.
45. Smith RE, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-8.
46. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17.
47. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEpo): A prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 2003;64:102-10.
48. Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005;23: 2597-605.
49. Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial. J Pain Symptom Manage 2003;25:512-8.
50. Janinis J, Dafni U, Aravantinos G, Kalofonos HP, Papakostas P, Tsavdaridis D, et al. Quality of life (QoL) outcome of epoetin-alfa (EPO-A) in anemic cancer patients undergoing platinum or non-platinum-based chemotherapy: A randomized study conducted by the Hellenic Cooperative Oncology Group. Proceedings of ASCO. May 31, 2003. 39th Annual Meeting of the American Society of Clinical Oncology, May 31 to June 3, 2003, Chicago, IL. Abstract 3172.
51. Savonije J, Van Groeningen C, Van Bochove A, Pinedo H, Giaccone G. Early intervention with epoetin-alfa during platinum-based chemotherapy. J Clinical Oncology 22[14S]. June 5, 2004. 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. Abstract 8111.
52. Thomas H, McAdam KF, Thomas RJ, Joffe JK, Sugden EM, Awwad ST, et al. Early intervention with epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. Ann Oncol 13(Suppl 5):177. October 18, 2002. 27th European Society for Medical Oncology, 18-22 October 2002, Nice, France. Abstract 653p.
53. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20.
54. Machtay M, Pajak T, Suntharalingam M, Hershock D, Stripp DC, Cmelak A, et al. Definitive radiotherapy±erythropoietin for squamous cell carcinoma of the head and neck: Preliminary report of RTOG 99-03. Int J Radiat Oncol Biol Phys 60(1 suppl): S132. October 3, 2004. Proceedings of the American Society for Therapeutic Radiology and Oncology 46th annual meeting. Georgia World Congress Center, October 3-7, 2004, Atlanta, GA.
55. O'Shaugnessy J, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, et al. Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neo-adjuvant chemotherapy. Clin Breast Cancer 2005;5:439-46.
56. Vadhan-Raj S, Skibber JM, Crane C, Buesos-Ramos CE, Rodriguez-Bigas MA, Feig BW, et al. Randomized, double-blind, placebo-controlled trial of epoetin alfa (Procrit) in patients with rectal and gastric cancer undergoing chemo-radiotherapy (CT/RT) followed by surgery: Early termination of the trial due to increased incidence of thrombo-embolic events (TEE). Blood 104:797a. December 4, 2004. 46th Annual Meeting of the American Sociey of Hematology, Dec 4-7, 2004, San Diego, CA. Abstract 2915.
57. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO GBR-07; 2004.
58. Henze G, Michon J, Morland B, Perek D, Rizzari C, Zoubek A, et al. Phase III randomized study: Efficacy of epoetin alfa in reducing blood transfusions in newly diagnosed pediatric cancer patients receiving chemotherapy. Proceedings of ASCO 21. May 18, 2002. 38th Annual Meeting of American Society of Clinical Oncology, May 18-21, 2002 Orlando, FL. Abstract 1547.
59. Huddart RA, Welch RS, Chan S, Perren T, Atkinson R. A prospective randomised comparative-group evaluation of epoetin alfa for the treatment of anaemia in UK cancer patients receiving platinum-based chemotherapy. Ann Oncol 2002;13(Suppl 5):177.
60. Rosenzweig MQ, Bender CM, Lucke JP, Yasko JM, Brufsky AM. The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. J Pain Symptom Manage 2004;27:185-90.
61. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO-CAN-15; 2004.
62. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, EPO-CAN-20. May 4, 2004.
63. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, GOG-191. May 4, 2004.
64. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, INT-1, May 4, 2004.
65. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, INT-3, May 4, 2004.
66. Hearings Before the Subcommittee on Oncologic Drugs Advisory Committee of the House Committee on Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research, N93 004. May 4, 2004.
67. Osterborg A, Brandberg Y, Hedenus M. Impact of epoetin-b on survival of patients with lymphoproliferative malignanices: Long-term follow up of a large randomized study. Br J Haematol 2005;129:206-9.
68. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-72.
69. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514-20.
70. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104: 2822-9.
71. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropietin receptor expression in human cancer. Cancer Res 2001;61:3561-5.
72. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 2002;82:911-8.
73. Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003;24:1021-9.
74. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004;83: 673-86.
75. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. Erythropoietin and erythropoietin receptor expression in head and neck cancer: Relationship to tumor hypoxia. Clin Cancer Res 2005;11:20-7.
76. Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, et al. Multicenter randomized phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 2003;9:1689-97.
77. Michael U, Jackisch C, Lenhard MS, Du Bois A, Lueck H, Thomssen C, et al. Epoetin-alpha reduces red blood cell transfusions (RBC) in high-risk breast cancer patients with adjuvant dose-dense, sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamid (C) (ETC). J Clin Oncol. May 13, 2005. 41st Annual Meeting of the American Society of Clinical Oncology, May 13-17, 2003, Orlando, FL. Abstract 613.
78. Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Final results of a randomized phase III study. Eur J Cancer 2001;37(Suppl 6):S144.
79. Blohmer JU, Wurschmidt F, Petry U, Weise G, Sehouli J, Kimming R, et al. Results with sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervial cancer: Results of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study. Ann Oncol 15(Suppl 3). October 29, 2004. 29th European Society for Medical Oncology Congress, 29 October to 2 November 2004, Vienna, Austria. Abstract 447PD.
80. Boogaerts M, Coiffier B, Kainz C, and the Epoetin Beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88: 988-95.